Viagra — and a reduced risk of developing Alzheimer’s disease. In a large analysis of insurance claims data involving more than 7 million individuals, researchers found that sildenafil users had a 69% lower incidence of Alzheimer’s disease compared with non-users. The study also suggested potential biological mechanisms, including improved cerebral blood flow and effects on cellular pathways involved in neuron growth and tau protein regulation.
However, researchers caution that these findings demonstrate correlation, not causation. Because the study was observational, it cannot prove that sildenafil directly prevents Alzheimer’s disease. Other factors — such as overall cardiovascular health, lifestyle differences, or healthcare access — may partly explain the association. Clinical trials are therefore needed to determine whether sildenafil can truly prevent or slow cognitive decline.
Although the results are promising, sildenafil is not currently approved for the prevention or treatment of Alzheimer’s disease. Ongoing research will determine whether this widely used medication could eventually be repurposed as a therapy for neurodegenerative disorders.
Source: Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer’s disease by Jiansong Fang et al., published in Nature Aging.
0 Comment:
Post a Comment